FORT LAUDERDALE, Florida, June 11, 2020 — ImmunSYS, Inc., a clinical-stage biopharmaceutical company focused on the development of innovative cancer immunotherapy products, announced today the appointment of George C. Prendergast, PhD, a leading researcher and pioneer in immune therapies, to their scientific advisory board, effective April 2020.
“We are honored to welcome Dr. Prendergast to our scientific advisory board,” said Eamonn Hobbs, Chairman and Chief Executive Officer of ImmunSYS. “As a distinguished, well-respected leader in the cancer immunotherapy field, we know Dr. Prendergast will enhance our strategic efforts and provide important guidance through the next phase of our development.”
“I’m pleased to join this group of internationally recognized experts and look forward to working with the ImmunSYS team on the clinical development of the YourVaccx™ platform,” said Dr. Prendergast.
Dr. Prendergast is the President and CEO of the Lankenau Institute for Medical Research (LIMR) and led the discovery and development of indoleamine 2,3 dioxygenase-1 (IDO1) inhibitors as anti-cancer agents. He was Editor-in-Chief of Cancer Research, a peer-reviewed and highly cited scientific journal published by the American Association for Cancer Research (AACR) from 2010-2017. He is a graduate of the University of Pennsylvania, where as a Benjamin Franklin Scholar he earned a bachelor’s degree magna cum laude with distinction in Biochemistry. He received his master’s degree in Molecular Biophysics and Biochemistry from Yale University and his doctorate in Molecular Biology from Princeton University.
After obtaining advanced training as an American Cancer Society postdoctoral fellow at the Howard Hughes Medical Institute at NYU Medical Center, he joined the Department of Cancer Research at Merck Research Laboratories. In 1993, Dr. Prendergast was appointed assistant professor and later associate professor at The Wistar Institute in Philadelphia, where he was designated a Pew Scholar in the Biomedical Sciences. Subsequently, he became the senior director of the Cancer Research Group at the DuPont Pharmaceutical Company. In 2002, he moved his research efforts at Wistar and DuPont to LIMR. He brings a wealth of experience in basic and clinical oncology research, preclinical drug discovery and development.
ImmunSYS, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative cancer immunotherapy products to improve the lives of patients with metastatic prostate cancer and other metastatic solid tumors.
ImmunSYS is committed to bringing life-changing treatments to patients with metastatic cancer. The Company’s platform technology, YourVaccx, empowers the immune system to generate a strong anticancer effect, potentially creating abscopal effects through the combination of cryosurgical cellular lysis and the intratumoral delivery of a proprietary triple-component immunotherapeutic drug that is in development.
The YourVaccx therapy has the potential to offer patients with metastatic solid tumors benefits over the existing standard of care. The company’s lead development program is the treatment of metastatic prostate cancer, followed by a pipeline of development programs for other metastatic solid tumors. For more information about the company and its programs, visit www.immunsys.com. Follow and connect with us on Twitter, Facebook, YouTube and LinkedIn.
Cautionary Note Regarding Forward-Looking Statements
This news release contains forward-looking statements. Forward-looking statements can be identified by words such as “anticipate,” “intend,” “plan,” “goal,” “seek,” “believe,” “project,” “expect,” “strategy,” “future,” “likely,” “may,” “should,” “will” and other words and terms of similar meaning. The forward-looking statements contained in this news release include, but are not limited to, statements relating to future clinical results and the effectiveness of the Company’s therapies. These forward-looking statements are subject to risks, uncertainties and other factors. Accordingly, actual results may differ significantly from those projected in the forward-looking statements contained herein. Readers should not place undue reliance on these forward-looking statements. The forward-looking statements included in this news release are made only as of the date hereof, and the Company does not undertake any obligation to update any forward-looking statements to reflect subsequent events or circumstances, except as required by applicable law.
Joseph Gerardi, +1-518-796-6110
Executive Vice President, Chief Financial Officer